PMADS

Id:	acc2010
Group:	2sens
Protein:	PIN1
Gene Symbol:	PIN1
Protein Id:	Q13526
Protein Name:	PIN1_HUMAN
PTM:	phosphorylation
Site:	Ser115
Site Sequence:	LASQFSDCSSAKARGDLGAFS
Disease Category:	Cancer
Disease:	Cholangiocarcinoma
Disease Subtype:	Intrahepatic cholangiocarcinoma (ICC)
Disease Cellline:
Disease Info:
Drug:	retinoic acid
Drug Info:	"Retinoic acid (also known as tretinoin or vitamin A acid) is a potent metabolite of vitamin A that regulates cell growth, differentiation, and organogenesis by acting as a natural agonist of retinoic acid receptors (RARs) and modulating gene transcription."
Effect:	modulate
Effect Info:	Inhibiting PIN1 with all-trans retinoic acid can suppress the growth of ICC cells.
Note:
Score:	4.0
Pubmed(PMID):	34048060
Sentence Index:	34048060_7-8
Sentence:	"Mechanistically, the JNK kinases directly bind to and phosphorylate PIN1 at Ser115, and this phosphorylation prevents PIN1 mono-ubiquitination at Lys117 and its proteasomal degradation. Moreover, pharmacological inhibition of PIN1 through all-trans retinoic acid, a Food and Drug Administration-approved drug, impairs the growth of both cultured and xenografted ICC cells."

Sequence & Structure:

MADEEKLPPGWEKRMSRSSGRVYYFNHITNASQWERPSGNSSSGGKNGQGEPARVRCSHLLVKHSQSRRPSSWRQEKITRTKEEALELINGYIQKIKSGEEDFESLASQFSDCSSAKARGDLGAFSRGQMQKPFEDASFALRTGEMSGPVFTDSGIHIILRTE

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CIAPIN1-Ser169
Cancer	Intensity
BRCA
COAD	-0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

CIAPIN1-Ser170
Cancer	Intensity
BRCA
COAD	0.41
HGSC	-1.283
ccRCC	-0.198
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	1.071

CIAPIN1-Ser172
Cancer	Intensity
BRCA	-1.014
COAD	-0.658
HGSC	1.844
ccRCC	-0.309
GBM	-0.152
HNSC	0.529
LUAD
LUSC
non_ccRCC	-1.045
PDAC	0.805
UCEC

CIAPIN1-Ser259
Cancer	Intensity
BRCA	1.507
COAD
HGSC
ccRCC	-0.97
GBM	0.251
HNSC	-1.057
LUAD	-0.575
LUSC	-0.128
non_ccRCC	1.432
PDAC
UCEC	-0.46

CIAPIN1-Ser274
Cancer	Intensity
BRCA	-1.323
COAD	0.182
HGSC
ccRCC	0.233
GBM	-0.279
HNSC	-0.566
LUAD	-0.513
LUSC	-0.885
non_ccRCC	2.309
PDAC	0.294
UCEC	0.548

CIAPIN1-Thr123
Cancer	Intensity
BRCA	0.775
COAD
HGSC	-2.361
ccRCC	-0.204
GBM	0.078
HNSC	0.575
LUAD	0.928
LUSC	0.238
non_ccRCC	0.23
PDAC	0.719
UCEC	-0.978

CIAPIN1-Tyr277
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Ser112
Cancer	Intensity
BRCA
COAD	-0.284
HGSC	1.23
ccRCC
GBM	0.579
HNSC
LUAD	-0.799
LUSC
non_ccRCC
PDAC	0.679
UCEC	-1.405

LPIN1-Ser168
Cancer	Intensity
BRCA	-0.736
COAD	0.363
HGSC	2.162
ccRCC
GBM	-0.596
HNSC	0.254
LUAD	0.234
LUSC	0.252
non_ccRCC
PDAC	-0.614
UCEC	-1.319

LPIN1-Ser258
Cancer	Intensity
BRCA	-1.462
COAD
HGSC	-1.645
ccRCC	0.833
GBM	0.439
HNSC	0.69
LUAD
LUSC	0.754
non_ccRCC
PDAC	0.469
UCEC	-0.077

LPIN1-Ser299
Cancer	Intensity
BRCA	-0.826
COAD
HGSC	1.112
ccRCC
GBM
HNSC	-0.286
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Ser300
Cancer	Intensity
BRCA
COAD	-0.136
HGSC	-0.925
ccRCC
GBM
HNSC	1.061
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Ser444
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Ser455
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Ser893
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Ser895
Cancer	Intensity
BRCA
COAD	0.051
HGSC	-1.025
ccRCC
GBM	0.973
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LPIN1-Thr111
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PIN1-Ser154
Cancer	Intensity
BRCA	-0.379
COAD
HGSC	-1.604
ccRCC
GBM	0.048
HNSC	1.459
LUAD
LUSC	0.099
non_ccRCC
PDAC	0.378
UCEC

PIN1-Thr152
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.348
GBM	-0.212
HNSC	-1.256
LUAD	1.121
LUSC
non_ccRCC
PDAC
UCEC

REPIN1-Ser498
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.707
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

REPIN1-Ser84
Cancer	Intensity
BRCA	-1.459
COAD
HGSC
ccRCC
GBM
HNSC	0.962
LUAD	-0.241
LUSC	0.924
non_ccRCC
PDAC
UCEC	-0.186

REPIN1-Thr455
Cancer	Intensity
BRCA	-0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	0.707
non_ccRCC
PDAC
UCEC

SPIN1-Ser124
Cancer	Intensity
BRCA	-0.468
COAD
HGSC	1.789
ccRCC	0.075
GBM	0.299
HNSC	0.125
LUAD	0.203
LUSC	0.036
non_ccRCC
PDAC	0.043
UCEC	-2.104

SPIN1-Ser199
Cancer	Intensity
BRCA	0.291
COAD	-0.351
HGSC	-0.068
ccRCC	1.193
GBM
HNSC	0.694
LUAD	0.641
LUSC	-0.307
non_ccRCC
PDAC	-2.092
UCEC

SPIN1-Ser39
Cancer	Intensity
BRCA	-0.374
COAD	-0.759
HGSC	1.133
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	115	U	Intrahepatic cholangiocarcinoma	Phosphorylation	34048060

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb